Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Aclarion, Inc. ( (ACON) ) has provided an announcement.
On April 21, 2026, Aclarion, Inc.’s board of directors authorized a share repurchase program of up to $2.5 million of its outstanding common stock, with the company planning to execute buybacks over the next 12 months using existing cash and cash equivalents. As of March 31, 2026, Aclarion held about $19 million in cash and cash equivalents, and management said the program reflects confidence in the firm’s valuation and its ability to fund operations through key milestones, while balancing Nociscan growth investment with disciplined capital management.
The repurchases may be conducted through various methods, including open market purchases, privately negotiated transactions, block trades, accelerated share repurchases and 10b5-1 trading plans, and the company is not obligated to buy a specific number of shares and can modify or suspend the program at any time. Executives framed the move as a flexible tool to enhance shareholder value without compromising financial flexibility, signaling Aclarion’s intent to support continued adoption and expansion of its Nociscan platform while actively managing its capital structure.
The most recent analyst rating on (ACON) stock is a Buy with a $7.00 price target. To see the full list of analyst forecasts on Aclarion, Inc. stock, see the ACON Stock Forecast page.
More about Aclarion, Inc.
Aclarion, Inc. is a commercial-stage healthcare technology company that leverages magnetic resonance spectroscopy, proprietary signal processing, biomarkers and augmented intelligence algorithms to optimize clinical treatments. The company is initially focused on the chronic low back pain market through its Nociscan SaaS platform, which helps physicians distinguish between painful and nonpainful lumbar discs to improve treatment decisions.
Nociscan operates via a cloud-based connection that receives MRS data from MRI machines for each lumbar disc being evaluated and extracts chemical biomarkers associated with disc pain. These biomarkers are processed through proprietary algorithms to indicate whether a disc may be a source of pain, providing physicians with critical insights into pain location when used alongside other diagnostic tools.
Average Trading Volume: 95,039
Technical Sentiment Signal: Sell
Current Market Cap: $8.1M
Find detailed analytics on ACON stock on TipRanks’ Stock Analysis page.